Recombinant RSV vaccines

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9492531
APP PUB NO 20120093847A1
SERIAL NO

13378391

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

This disclosure provides recombinant respiratory syncytial virus (RSV) antigens and methods for making and using them, including immunogenic compositions (e.g., vaccines) for the treatment and/or prevention of RSV infection.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

  • ID BIOMEDICAL CORPORATION;GLAXOSMITHKLINE BIOLOGICALS SA

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Baudoux, Guy Jean Marie Fernand Pierre Rixensart, BE 6 78
Blais, Normand Laval, CA 30 174
Cyr, Sonya L Belgìque, BE 2 27
Rheault, Patrick Laval, CA 16 128
Ruelle, Jean-Louis Rixensart, BE 39 140

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 May 15, 2024
11.5 Year Payment $7400.00 $3700.00 $1850.00 May 15, 2028
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00